Beyond Air, Inc. (XAIR) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $5.4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.00%. A quarter ago, it was expected that this company would post a loss of $2.8 per share when it actually produced a loss of $1.8, delivering a surprise of +35.71%.Over the last four quarters, the company has surpasse ...

Beyond Air (XAIR) Q1 2026 Earnings Call August 12, 2025 04:30 PM ET Speaker0Good afternoon, and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter Ended 06/30/2025. At this time, participants are in a listen only mode. A question and answer session will follow the formal presentation. And now, I would like to turn the call over to Corey Davis from LifeSci Advisors. Please go ahead.Speaker1Thank you, operator. Good afternoon, everyone, and thank you for joining us. Today, after ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to _________ Commission File Number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) | Delaware | 47-3812456 | | --- | --- | | ...

GARDEN CITY, N.Y., July 25, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its first fiscal quarter ended June 30, 2025 on Tuesday, August 12, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the sa ...

GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, has been awarded a national group purchasing agreement for therapeutic gases with Premier, Inc. Effective July 15th, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated b ...

Core Viewpoint - Beyond Air, Inc. (XAIR) has experienced a downtrend, losing 13.7% over the past week, but a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottom formation, suggesting that selling pressure may be exhausting and that bulls could be regaining control [2][5]. - The hammer pattern is characterized by a small candle body with a long lower wick, indicating that the stock opened lower, made a new low, but closed near its opening price, reflecting buying interest [4][5]. - This pattern can occur across various timeframes and is utilized by both short-term and long-term investors [5]. Fundamental Analysis - Recent upward revisions in earnings estimates for XAIR serve as a bullish indicator, correlating strongly with near-term stock price movements [7]. - The consensus EPS estimate for the current year has increased by 40.5% over the last 30 days, indicating analysts' optimism about the company's earnings potential [8]. - XAIR holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED MARCH 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38892 BEYOND AIR, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 900 Stewart Avenue, Suite 301 ...

Fourth Quarter and Full Year 2025 Financial Results and Corporate Update [Overview and Highlights](index=1&type=section&id=Overview%20and%20Highlights) Beyond Air reported significant revenue growth for fiscal year 2025, driven by commercial expansion of its LungFit® PH system and strategic regulatory advancements, with strong revenue guidance for fiscal year 2026 Fiscal Year 2025 and 2026 Revenue Highlights | Metric | Value | Period | | :--- | :--- | :--- | | Revenue | $3.7 million | Fiscal Year 2025 | | Revenue Growth (YoY) | 220% | FY2025 vs FY2024 | | Expected Revenue | At least $1.7 million | Quarter ending June 30, 2025 | | Revenue Guidance | $12 - $16 million | Fiscal Year 2026 | - Submitted a Premarket Approval (PMA) supplement to the FDA for the **second-generation LungFit® PH system**, which is considered potentially transformative for the business[1](index=1&type=chunk)[3](index=3&type=chunk) - International distribution partnerships have expanded access to markets representing **over 2 billion people**, with active shipments to Europe, Australia, and the Middle East[1](index=1&type=chunk)[3](index=3&type=chunk) - Appointed Robert Goodman, a seasoned healthcare executive with a strong commercial background, to the Company's Board of Directors[1](index=1&type=chunk)[5](index=5&type=chunk) [Commercial Execution, Recent Highlights and Upcoming Milestones](index=2&type=section&id=Commercial%20Execution%2C%20Recent%20Highlights%20and%20Upcoming%20Milestones) The company is accelerating commercial adoption of LungFit® PH, expanding its market presence, and advancing key regulatory submissions and pipeline programs including Beyond Cancer and NeuroNOS - LungFit® PH is now installed and in regular use at more than **45 hospitals** nationwide[3](index=3&type=chunk) - Established a partnership with Vanderbilt University Medical Center (VUMC) as the first luminary site for LungFit PH[7](index=7&type=chunk) - Secured new distribution partnerships covering **over 25 countries**, including India, Italy, and several in the Middle East and Eastern Europe[7](index=7&type=chunk) - The FDA review for the cardiac surgery PMA supplement is ongoing; currently, no nitric oxide delivery system is approved for this indication[8](index=8&type=chunk) [Beyond Cancer - Solid Tumor Program](index=3&type=section&id=Beyond%20Cancer%20-%20Solid%20Tumor%20Program) The Beyond Cancer program is advancing clinical trials for its ultra-high concentration Nitric Oxide (UNO) therapy, with ongoing Phase 1a monotherapy and planned Phase 1b combination therapy trials - Phase 1a trial (monotherapy) for UNO therapy in solid tumors has completed the **25,000 ppm** dose cohort and is now evaluating the **50,000 ppm** dose[14](index=14&type=chunk) - Phase 1b trial (combination therapy) will assess UNO therapy in combination with an anti-PD-1 treatment for patients with disease progression[14](index=14&type=chunk) [NeuroNOS – Autism Spectrum Disorder (ASD) Program](index=3&type=section&id=NeuroNOS%20%E2%80%93%20Autism%20Spectrum%20Disorder%20%28ASD%29%20Program) The NeuroNOS program achieved significant milestones, including FDA Orphan Drug Designation for Phelan-McDermid Syndrome, preclinical data publication, and securing **$2 million** in equity financing for its autism drug - The U.S. FDA granted Orphan Drug Designation to BA-102 for the treatment of Phelan-McDermid Syndrome (PMS), a syndrome associated with ASD[14](index=14&type=chunk) - Completed a **$2 million** equity financing in NeuroNOS from private investors to accelerate preclinical development of its small-molecule drug for autism[14](index=14&type=chunk) - Appointed Nobel Prize laureate, Professor Dan Shechtman, to the NeuroNOS Scientific Advisory Board[14](index=14&type=chunk) [Financial Results and Guidance](index=3&type=section&id=Financial%20Results%20and%20Guidance) Beyond Air reported significant revenue growth for fiscal year 2025, alongside a reduced net loss and operating expenses, ending the year with a solid cash position and providing strong fiscal year 2026 revenue guidance Fiscal Year 2025 Financial Performance (Year Ended March 31, 2025) | Metric | FY 2025 (in millions) | FY 2024 (in millions) | YoY Change | | :--- | :--- | :--- | :--- | | Revenues | $3.7 | $1.2 | +220% | | Research and development | $16.9 | $24.4 | -30.7% | | Selling, general and administrative | $26.0 | $37.3 | -30.3% | | Net loss attributable to common stockholders | ($46.6) | ($60.2) | Improvement | | Net loss per share (basic and diluted) | ($0.69) | ($1.82) | Improvement | - As of March 31, 2025, the company had **$6.9 million** in cash, cash equivalents, and marketable securities, with **$12.2 million** in total long-term debt[17](index=17&type=chunk) - Cash burn for fiscal year 2025 was **$44.1 million**, excluding financing impacts[16](index=16&type=chunk) Fiscal Year 2026 Financial Guidance | Metric | Guidance | Period | | :--- | :--- | :--- | | Revenue | At least $1.7 million | Quarter ending June 30, 2025 | | Revenue | $12 - $16 million | Fiscal Year ending March 31, 2026 | [Financial Statements](index=7&type=section&id=Financial%20Statements) The consolidated balance sheet as of March 31, 2025, presents the company's financial position, while the statement of operations details the financial performance for the fiscal year 2025 Consolidated Balance Sheet Highlights (as of March 31, 2025) | Account (in thousands) | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $4,665 | $11,378 | | Total current assets | $16,018 | $43,936 | | **Total Assets** | **$30,062** | **$56,961** | | **Liabilities & Equity** | | | | Total current liabilities | $5,000 | $11,567 | | Long-term debt, net | $9,197 | $14,721 | | **Total Liabilities** | **$15,721** | **$29,775** | | **Total Equity** | **$14,341** | **$27,186** | Consolidated Statement of Operations Highlights (For the Year Ended March 31) | Account (in thousands) | 2025 | 2024 | | :--- | :--- | :--- | | Revenues | $3,705 | $1,159 | | Gross loss | ($1,663) | ($1,307) | | Loss from Operations | ($44,537) | ($63,006) | | Net loss | ($48,479) | ($64,295) | | Net loss attributable to Beyond Air, Inc. | ($46,625) | ($60,242) |

Company Overview - Beyond Oil Ltd. is a food-tech innovation company focused on reducing health risks associated with fried food while enhancing sustainability and lowering operational costs [5][7] - The company has developed patented technology that significantly reduces harmful compounds in frying oil, addressing critical health concerns [5][7] Health Risks and Findings - A Medical Opinion by Professor Dr. Ilan Ron highlights the health risks from repeated use of frying oil, including the formation of hazardous chemical byproducts with mutagenic and carcinogenic potential [1][3] - The Medical Opinion establishes a clear association between the consumption of heated oils and increased incidence of various cancers, particularly colorectal, liver, pancreatic, lung, and breast cancers [1][3] - Acrylamide (AA), a hazardous compound formed during frying, is linked to gastrointestinal inflammation, neurotoxicity, and carcinogenesis [2][3] Product Efficacy - Controlled experiments demonstrated that Beyond Oil's product effectively reduces harmful compounds in frying oil, maintaining quality close to fresh oil even after 22 to 51 days of use [3][6] - Key findings from the experiments include low levels of free fatty acids (FFA), significant reduction in carcinogens such as PAHs and AA, and stable oxidation and polymerization indicators [6][7] Recommendations and Implications - The Medical Opinion suggests integrating Beyond Oil's technology as a preventive measure in high-risk settings like schools, hospitals, and industrial kitchens, and promoting public health policies to limit the use of unfiltered reheated oils [4][7] - The endorsement from a leading oncologist underscores the significant health risks associated with reused frying oils and the need for innovative solutions like those offered by Beyond Oil [4][8]

Company Performance - Beyond Air, Inc. reported a quarterly loss of $0.09 per share, better than the Zacks Consensus Estimate of a loss of $0.14, and an improvement from a loss of $0.36 per share a year ago, representing an earnings surprise of 35.71% [1] - The company posted revenues of $1.15 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 17.12%, compared to year-ago revenues of $0.47 million [2] - Over the last four quarters, Beyond Air has surpassed consensus EPS estimates four times but has topped consensus revenue estimates only once [2] Stock Performance - Beyond Air shares have lost approximately 49.9% since the beginning of the year, while the S&P 500 has gained 2.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.12 on revenues of $1.99 million, and for the current fiscal year, it is -$0.42 on revenues of $13.66 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Beyond Air belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry performance can significantly impact stock performance [5][8]